ZNTL

Zentalis Pharmaceuticals Inc

Apr 09 • 04:00PM ET

4.42

+1.66 60.14 %

Healthcare • Biotechnology • USA • NASD

Apr 09, 8:05 AMZentalis selects 400mg once-daily 5:2 azenosertib monotherapy as pivotal dose for DENALI and ASPENOVA ovarian cancer trials

Peers: BMY LLY PFE JNJ MRK AMGN GILD BIIB VRTX REGN

| Held by: VTI VXF FESM IWC VHT PRFZ DFAS FSCC AVSC DFMC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	31.38%	Shs Outstand	69.09M	Perf Week	71.98%
Market Cap	313.52M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	-4.69%	Shs Float	48.67M	Perf Month	44.44%
Enterprise Value	107.21M	PEG	-	EPS next Q	-0.50	Inst Own	61.40%	Short Float	8.57%	Perf Quarter	82.64%
Income	-137.06M	P/S	-	EPS this Y	-6.03%	Inst Trans	-17.68%	Short Ratio	4.05	Perf Half Y	185.16%
Sales	0.00M	P/B	1.41	EPS next Y	21.05%	ROA	-38.11%	Short Interest	4.17M	Perf YTD	227.41%
Book/sh	3.13	P/C	1.28	EPS next 5Y	7.84%	ROE	-49.53%	52W High	3.95 11.90%	Perf Year	277.78%
Cash/sh	3.47	P/FCF	-	EPS past 3/5Y	24.78% 7.86%	ROIC	-54.41%	52W Low	1.01 337.62%	Perf 3Y	-75.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	17.85% 10.75%	Perf 5Y	-88.18%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.16%	Oper. Margin	-	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.93	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	78.41	Recom	2.11
Dividend Gr. 3/5Y	- -	Current Ratio	6.93	EPS Q/Q	26.26%	SMA20	66.37%	Beta	1.81	Target Price	5.81
Payout	-	Debt/Eq	0.18	Sales Q/Q	-100.00%	SMA50	73.48%	Rel Volume	15.06	Prev Close	2.76
Employees	106	LT Debt/Eq	0.17	Earnings	Mar 26 AMC	SMA200	138.53%	Avg Volume	1.03M	Price	4.42
IPO	Apr 03, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.18% -	Trades		Volume	15,874,761	Change	60.14%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-26	Resumed	Wells Fargo	Equal Weight	$5
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral	$4
Jun-20-24	Downgrade	UBS	Buy → Neutral	$28 → $5
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform	$15 → $4
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$38 → $8
Jun-18-24	Downgrade	Jefferies	Buy → Hold	$42 → $6
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral	$38 → $12
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform	$15
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight	$67
Oct-07-21	Resumed	Jefferies	Buy	$120
Sep-30-21	Initiated	Stifel	Buy	$84
Sep-29-21	Initiated	Oppenheimer	Outperform	$90
May-21-21	Initiated	UBS	Buy	$91
Jan-20-21	Initiated	Wedbush	Outperform	$65
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight	$44
Aug-27-20	Initiated	H.C. Wainwright	Buy	$43
Apr-28-20	Initiated	SVB Leerink	Outperform	$45
Apr-28-20	Initiated	Morgan Stanley	Overweight	$45

Show Previous Ratings

Apr-09-26 08:00AM	Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer (GlobeNewswire) +60.14%
Apr-01-26 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.83%
Mar-26-26 04:05PM	Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates (GlobeNewswire) -21.35%
Mar-17-26 04:30PM	Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire) -7.88%
Feb-18-26 08:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
05:09AM	Loading…
Feb-16-26 05:09AM	Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon (MarketBeat)
Feb-03-26 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +12.35% -9.57%
Jan-13-26 08:45AM	Mitsui Sumitomo Continues to Build WR Berkley Stake (24/7 Wall St.)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire) -6.68%
Jan-06-26 08:00AM	Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 (GlobeNewswire) +29.93%
Nov-10-25 04:05PM	Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +6.06%
Nov-03-25 05:25PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.33%
08:15AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-13-25 04:05PM	Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-01-25 05:20PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.79%
05:00PM	Loading…
Sep-02-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-25 04:15PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-25 04:05PM	Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Aug-06-25 04:05PM	Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.07%
Jul-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79% +6.25%
May-14-25 04:05PM	Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.88%
May-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 08:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC (GlobeNewswire)
Apr-23-25 04:05PM	Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-01-25 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.58%
Mar-26-25 04:05PM	Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -5.88%
Mar-25-25 04:40PM	Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.56%
Mar-15-25 11:25AM	Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Mar-03-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.25%
08:00AM	Loading…
08:00AM	Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Feb-24-25 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-25 12:21AM	Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently (Insider Monkey) -6.07%
Feb-03-25 05:42PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:35AM	Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-30-25 10:20AM	Zentalis price target lowered to $10 from $20 at Oppenheimer (TipRanks) -12.17%
Jan-29-25 07:00AM	Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer (GlobeNewswire) -21.25%
Jan-28-25 04:05PM	Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development (GlobeNewswire)
Jan-09-25 12:00PM	Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies (GlobeNewswire)
Jan-02-25 04:53PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.00%
Dec-12-24 07:00AM	Zentalis Pharmaceuticals Announces Key Management Appointments (GlobeNewswire) -10.57%
Dec-02-24 04:35PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Nov-13-24 08:00AM	Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib (GlobeNewswire) +5.66%
Nov-01-24 07:04PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings (GuruFocus.com)
Oct-07-24 03:03PM	FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc (GuruFocus.com) -7.72%
Sep-17-24 12:15PM	FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor (Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM	FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers (Benzinga) +13.58%
07:00AM	Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies (GlobeNewswire)
Sep-09-24 07:00AM	Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 (GlobeNewswire)
Sep-03-24 04:40PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.92%
Aug-26-24 11:58AM	Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why (Zacks)
Aug-09-24 02:53PM	ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024 (InvestorPlace) -9.37%
07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
Aug-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.00%
Jul-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.80%
Jun-19-24 10:23AM	Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold (Zacks)
04:52AM	FDA places partial clinical hold on Zentalis trials of azenosertib for cancer (Clinical Trials Arena)
Jun-18-24 07:00AM	Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program (GlobeNewswire) -50.66%
Jun-03-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-24 02:43AM	Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ... (GuruFocus.com)
May-30-24 07:00AM	Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors (GlobeNewswire)
May-23-24 05:01PM	Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -5.84%
May-14-24 07:00AM	Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-08-24 10:27AM	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating (MT Newswires)
May-07-24 09:04PM	Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ... (GuruFocus.com) +5.03%
01:54PM	ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
May-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 04:05PM	Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 (GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:55AM	Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet (Zacks) +5.30%
07:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 07:01PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ... (GuruFocus.com)
07:00AM	Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Feb-14-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL) (Zacks) +10.34%
Feb-13-24 07:00AM	Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire) -5.83%
Feb-08-24 12:00PM	What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock (Zacks)
Feb-05-24 11:26PM	Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Feb-01-24 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-25-24 07:00AM	Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments (GlobeNewswire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.15%
Jan-02-24 04:49PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.54%
Dec-01-23 05:39PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-23 09:03PM	Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares (GuruFocus.com) +14.42%
Nov-09-23 07:00AM	Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen (GlobeNewswire)
Nov-06-23 07:13PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com) -30.20% -18.27%
07:18AM	Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Nov-01-23 04:52PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-23 05:00AM	Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ... (GuruFocus.com)
Oct-02-23 04:27PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-23 01:02AM	Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Sep-06-23 07:00AM	Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-01-23 04:37PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Aug-09-23 07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-23 04:28PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer (GlobeNewswire)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bruns Ingmar	Chief Medical Officer	Feb 06 '26	Sale	2.43	2,962	7,197	33,667	Feb 10 09:10 PM
Bruns Ingmar	Chief Medical Officer	Feb 09 '26	Sale	2.39	335	802	33,332	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 06 '26	Sale	2.43	29,951	72,772	156,779	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 10 '26	Sale	2.42	6,894	16,699	146,506	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 09 '26	Sale	2.39	3,379	8,086	153,400	Feb 10 09:10 PM
EASTLAND JULIA MARIE	CEO & President	Feb 06 '26	Sale	2.43	7,866	19,112	80,022	Feb 10 09:09 PM
EASTLAND JULIA MARIE	CEO & President	Feb 09 '26	Sale	2.39	889	2,127	79,133	Feb 10 09:09 PM
Vultaggio Vincent	PAO and PFO	Feb 02 '26	Sale	2.55	2,540	6,477	187,286	Feb 04 08:27 PM
Vultaggio Vincent	PAO and PFO	Feb 03 '26	Sale	2.52	556	1,398	186,730	Feb 04 08:27 PM
WALTERS GROUP	10% Owner	Dec 31 '25	Buy	1.20	6,459,973	7,751,968	13,509,973	Jan 08 04:57 PM
Matrix Capital Management Comp	10% Owner	Dec 15 '25	Sale	1.33	7,500,000	9,975,000	6,459,973	Dec 15 05:24 PM
Myers Scott Dunseth	Director	Apr 30 '25	Buy	1.40	21,000	29,373	281,192	Apr 30 05:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZNTL

Zentalis Pharmaceuticals Inc

Upgrade your Finviz experience